Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR. - Wikidata - wikimedia - TriplyDB

Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.

Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.

http://www.wikidata.org/entity/Q37384489

about

Acute reductions in mechanical wall strain precede the formation of intimal hyperplasia in a murine model of arterial occlusive disease.Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice.Application of in utero electroporation of G-protein coupled receptor (GPCR) genes, for subcellular localization of hardly identifiable GPCR in mouse cerebral cortex.Lysophosphatidic acid in atherosclerotic diseases Aiming drug discovery at lysophosphatidic acid targets.Lysophosphatidic acid induces integrin activation in vascular smooth muscle and alters arteriolar myogenic vasoconstriction.Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.Vascular involvement in systemic sclerosis (scleroderma).Pathogenesis of Systemic Sclerosis.Pharmacological repression of PPARγ promotes osteogenesis Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid.Lysophosphatidic Acid and Sphingosine-1-Phosphate: A Concise Review of Biological Function and Applications for Tissue Engineering.Nicorandil attenuates carotid intimal hyperplasia after balloon catheter injury in diabetic rats.LPA/PKD-1-FoxO1 Signaling Axis Mediates Endothelial Cell CD36 Transcriptional Repression and Proangiogenic and Proarteriogenic Reprogramming.Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis.G-protein-mediated signaling in vascular smooth muscle cells - implications for vascular disease.Lysophosphatidic acid-induced vascular neointimal formation in mouse carotid arteries is mediated by the matricellular protein CCN1/Cyr61.Lysophosphatidic acid effects on atherosclerosis and thrombosis.Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia.Cyclic phosphatidic acid inhibits alkyl-glycerophosphate-induced downregulation of histone deacetylase 2 expression and suppresses the inflammatory response in human coronary artery endothelial cells.

P2860

Q30399953-F71A251B-0DC3-47A0-80EB-1492E48412E7 Q30410474-8221900B-7445-4A1E-AABB-28A0EE6EFFB9 Q34043023-3172203F-1A04-40C4-8B56-BE3729D32DEB Q34273486-4EACEEF4-3394-4A83-BE4B-0B643E8AD932 Q34339759-DCEFD230-F3B6-451E-ACB5-8DEC4F426BD8 Q34433358-F7F57572-02DB-41F1-AFCE-DB93AC210543 Q35551835-020CC2A1-EC9A-44B7-ADD8-63B7C46982C9 Q35557424-9189A8B6-2DB4-4E26-8537-42AF9862A039 Q35693212-4D9201D9-53BE-4E3A-962E-74266D086F12 Q35754510-D88149E7-C57F-4447-BC53-828DBE42FE16 Q36246883-3D9C91D1-92C8-4F21-BFBA-80F15B27FEA5 Q36330107-E9C28095-B838-402D-8A4E-CC3E072A0BCC Q36783324-B9F7EE0B-6FDC-4F37-8F94-48B40AD91B06 Q36940630-8418FE97-2F17-42B4-91CC-4A4166108A78 Q37620329-5AB4F48F-4490-49C5-9A74-DCDDE571B065 Q38526491-3E1415C6-FFAB-41BE-BFD7-0D730A15A035 Q39269910-2837AC8B-0846-4702-B270-8D0D0646DAE0 Q39608397-34C0CE6F-3262-4DE6-AA03-7B1F8194C45A Q42414579-141D6089-B39B-43CF-BE16-92F5DEA66079 Q42720236-460F7494-CB7A-464C-A188-D4D09E844E17

P2860

Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.

http://www.wikidata.org/entity/Q37384489

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Lysophosphatidic acid-induced ...... mma but not LPA1 or LPA2 GPCR.

@en

Lysophosphatidic acid-induced ...... mma but not LPA1 or LPA2 GPCR.

@nl

type

label

Lysophosphatidic acid-induced ...... mma but not LPA1 or LPA2 GPCR.

@en

Lysophosphatidic acid-induced ...... mma but not LPA1 or LPA2 GPCR.

@nl

prefLabel

Lysophosphatidic acid-induced ...... mma but not LPA1 or LPA2 GPCR.

@en

Lysophosphatidic acid-induced ...... mma but not LPA1 or LPA2 GPCR.

@nl

P1433

Q37384489-0311E0CD-4372-4E79-8385-057BEE66BD34

P1476

Q37384489-47229CBC-1107-496B-98FE-EC48825E72C1

P2093

Q37384489-264033D0-7C27-4052-B0E6-24B7EB48F127

Q37384489-37F5A017-C347-4E90-A124-20FABED6A25F

Q37384489-4CC60317-146E-4FA3-8254-B92127A5C237

Q37384489-4ED086EF-463F-40BA-8D7A-E64C802EF87B

Q37384489-615D263B-A643-4191-BEE1-62B1D65F070F

Q37384489-6793BDC1-9802-4DB3-A5B2-61930BA3F7CA

Q37384489-955E505D-B1CC-4264-B1E3-E78743CA0CA7

Q37384489-BBC7C8EA-05BA-40D8-BBF2-B3B5CF9346E9

Q37384489-E0BEB763-FD9B-45AD-BCAA-EF64FB0DAEB6

P2860

Q37384489-02198E26-4F34-4AD1-8D73-EA0B33C15765

Q37384489-034FBEEC-5980-4438-BDBA-A74B200068B7

Q37384489-0A5AC79B-5D79-48FE-B38A-A680508893E7

Q37384489-12F01BE9-C0D0-450F-B43A-95C0B26C8409

Q37384489-21A4FF63-E636-41A8-ABA9-4E887EE809B3

Q37384489-30955933-2414-4EE3-AEE2-D6457FDB951F

Q37384489-470F8DA4-DF62-4EBC-A2E8-645531AA814B

Q37384489-49C7154A-ABE7-45CB-9508-F9118E0784AF

Q37384489-4B9D7A96-065B-406C-BCED-7FFC7AAA5927

Q37384489-4CA3B054-B9BF-4BB4-81CF-293BF9F62EB0

P304

Q37384489-14A747A0-0E7D-42A6-90E7-720C8A9B4EA3

P31

Q37384489-BC7B17AA-AF8C-4CDE-B1A2-B432205271DA

P356

Q37384489-BCEE77AC-565A-44BA-967B-0E301B068B80

P433

Q37384489-52647941-7308-411B-BFE0-12EFCDBE3794

P478

Q37384489-2694E489-0697-49DA-84CF-5D7BD89B7067

P577

Q37384489-8A7BD5AF-FD6F-4E9F-B2D2-ED7676916A50

P5875

Q37384489-95292E2F-3A8D-4181-BD1A-8367DE5EE3D2

P698

Q37384489-0F0F875A-9DFA-4F4C-99D7-D350E81970D0

P921

Q37384489-53654ABD-23FF-4687-BC9A-BE7B2E87314A

P932

Q37384489-61569041-9AF3-4DAA-B0E4-FB0E8E33BDCA

P356

J.CELLSIG.2009.08.003

P1433

Cellular Signalling

P1476

Lysophosphatidic acid-induced ...... mma but not LPA1 or LPA2 GPCR.

@en

P2093

Chunxiang Zhang

http://www.w3.org/2001/XMLSchema#string

E Shuyu

http://www.w3.org/2001/XMLSchema#string

Gabor Tigyi

http://www.w3.org/2001/XMLSchema#string

Huazhang Guo

http://www.w3.org/2001/XMLSchema#string

Louisa Balazs

http://www.w3.org/2001/XMLSchema#string

Natalia Makarova

http://www.w3.org/2001/XMLSchema#string

Patricia Farrar

http://www.w3.org/2001/XMLSchema#string

Ryoko Tsukahara

http://www.w3.org/2001/XMLSchema#string

Yunhui Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance

Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors

Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions

Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.

Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2).

Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist.

In vivo roles of lysophospholipid receptors revealed by gene targeting studies in mice.

Stereochemical properties of lysophosphatidic acid receptor activation and metabolism.

The macrophage foam cell as a target for therapeutic intervention.

Thrombogenic and atherogenic activities of lysophosphatidic acid.

P304

1874-1884

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELLSIG.2009.08.003

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26769628

http://www.w3.org/2001/XMLSchema#string

P698

19709640

http://www.w3.org/2001/XMLSchema#string

P921

G protein-coupled receptor

P932

2760670

http://www.w3.org/2001/XMLSchema#string